NCT06585176

Brief Summary

Gastroesophageal Reflux Disease (GERD) is a condition characterized by the reflux of gastric and duodenal contents into the esophagus, primarily manifested by symptoms such as acid regurgitation and heartburn. GERD significantly affects patients' daily lives and health-related quality of life. Prolonged gastroesophageal reflux can lead to repeated irritation of the esophageal mucosa by gastric acid and acidic gastric contents, resulting in the replacement of normal squamous epithelium in the lower esophagus with metaplastic columnar epithelium. This pathological change, known as Barrett's Esophagus (BE), is considered a precancerous lesion for esophageal adenocarcinoma.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,625

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Aug 2024

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2024

Completed
25 days until next milestone

First Submitted

Initial submission to the registry

August 26, 2024

Completed
10 days until next milestone

First Posted

Study publicly available on registry

September 5, 2024

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 31, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 31, 2025

Completed
Last Updated

March 13, 2026

Status Verified

March 1, 2026

Enrollment Period

1.2 years

First QC Date

August 26, 2024

Last Update Submit

March 11, 2026

Conditions

Keywords

Gastroesophageal reflux diseasesBarrett esophageal

Outcome Measures

Primary Outcomes (3)

  • The prevalence of GERD in Xiamen city

    Gastroesophageal reflux disease (GERD) is the most prevalent gastrointestinal disorder in the world. In this study, we will study the incidence of GERD in Xiamen city.

    3 months.

  • The percentage of reflux esophagitis

    The percentage of participants diagnosed with reflux esophagitis using endoscopy among patients with baseline symptoms.

    3 months.

  • The percentage of Barrett esophagus

    The percentage of paticipants diagnosed with pathological Barrett esophagus using endoscopy monitoring among patients with baseline symptom in gastroenterology department will be calculated.

    3 months.

Secondary Outcomes (3)

  • The life quality of GERD patients who were diagnosed by endoscopy

    3 months.

  • The sensitivity of GERD-Q for diagnosis of GERD

    3 months.

  • The specificity of GERD-Q for diagnosis of GERD

    3 months.

Study Arms (1)

Gastroesophageal Reflux Disease

Gastroesophageal reflux disease (GERD) is a gastrointestinal motility disorder that results from the reflux of stomach contents into the esophagus or oral cavity resulting in symptoms or complications.

Other: No intervention

Interventions

This concerns a natural history study. No interventions will be used.

Gastroesophageal Reflux Disease

Eligibility Criteria

Age16 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Gastroesophageal reflux disease (GERD) is a common digestive disorder in the general population that primarily affects the esophagus and gastro-duodenum. Due to its prevalence, GERD has a significant impact on quality of life and healthcare costs.

You may qualify if:

  • All patients had experienced typical reflux symptoms, i.e., mild heartburn and/or regurgitation symptoms, for at least 2 days per week or moderate/severe reflux symptoms for more than 1 day per week during the previous 3 months and had upper endoscopy examinations in the previous month.
  • Cooperate with the questionnaire survey.
  • Volunteer and sign the informed consent form.
  • Permanent residents in Xiamen.

You may not qualify if:

  • Malignant tumor.
  • Partial or total gastrectomy.
  • Failing to cooperate with the investigation because of the factors such as education level and language intelligence disorder, etc.
  • Patients with severe heart, lung, kidney, liver, blood, nerve, endocrine and mental system diseases.
  • Patients with mental retardation, etc.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Zhongshan Hospital (Xiamen), Fudan University

Xiamen, Fujian, 361015, China

Location

Related Publications (2)

  • Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol. 2022 Jan 1;117(1):27-56. doi: 10.14309/ajg.0000000000001538.

  • Chen Y, Sun X, Fan W, Yu J, Wang P, Liu D, Song M, Liu S, Zuo X, Zhang R, Hou Y, Han S, Li Y, Zhang J, Li X, Ke M, Fang X. Differences in Dietary and Lifestyle Triggers between Non-Erosive Reflux Disease and Reflux Esophagitis-A Multicenter Cross-Sectional Survey in China. Nutrients. 2023 Jul 31;15(15):3400. doi: 10.3390/nu15153400.

MeSH Terms

Conditions

Gastroesophageal Reflux

Condition Hierarchy (Ancestors)

Esophageal Motility DisordersDeglutition DisordersEsophageal DiseasesGastrointestinal DiseasesDigestive System Diseases

Study Officials

  • Wei Jiang, Doctor

    Zhongshan Hospital (Xiamen), Fudan University

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Deputy Chief Physician

Study Record Dates

First Submitted

August 26, 2024

First Posted

September 5, 2024

Study Start

August 1, 2024

Primary Completion

October 31, 2025

Study Completion

October 31, 2025

Last Updated

March 13, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will not share

Locations